Kura Oncology, Inc.

Equities

KURA

US50127T1097

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
21.17 USD +3.67% Intraday chart for Kura Oncology, Inc. -3.51% +47.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma CI
Transcript : Kura Oncology, Inc., 2023 Earnings Call, Feb 27, 2024
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia CI
Kura Oncology Says Study of Leukemia Combination Therapy Yields Positive Early Data MT
Transcript : Kura Oncology, Inc. - Special Call
Top Premarket Gainers MT
Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia CI
Kura Oncology, Inc. announced that it has received $150 million in funding from EcoR1 Capital, LLC CI
Kura Oncology Expects to Raise $150 Million in Gross Proceeds From Oversubscribed Private Placement MT
Top Premarket Gainers MT
Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC CI
Mizuho Securities Initiates Kura Oncology With Buy Rating, Price Target is $26 MT
Sector Update: Health Care Stocks Lean Lower Premarket Friday MT
Kura Oncology, The Leukemia & Lymphoma Society to Assess Ziftomenib With Chemotherapy in Children MT
Wedbush Lowers Kura Oncology's PT to $37 From $40, Adjusts Valuation, Market Assumptions After Q3 Results; Keeps Outperform Rating MT
Transcript : Kura Oncology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Rising Late Afternoon MT
Sector Update: Health Care Stocks Stronger Thursday Afternoon MT
Kura Oncology, Mirati Therapeutics Launch Collaboration, Supply Deal to Assess KO-2806, Adagrasib to Treat Lung Cancer MT
Kura Oncology, Inc. and Mirati Therapeutics, Inc. Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASG12C-Mutated NSCLC CI
Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806 CI
Chart Kura Oncology, Inc.
More charts
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.17 USD
Average target price
30.25 USD
Spread / Average Target
+42.89%
Consensus
  1. Stock
  2. Equities
  3. Stock Kura Oncology, Inc. - Nasdaq
  4. News Kura Oncology, Inc.
  5. Jefferies Financial Initiates Kura Oncology at Buy, Sets Price Target at $35